

DOI: <https://dx.doi.org/10.18203/2320-1770.ijrcog20243225>

Review Article

Prevention and management of urinary tract infection: a non-antibiotic multi-modal approach

Arif A. Faruqui*

Department of Pharmacology, Clinical Pharmacologist, Mumbai, Maharashtra, India

Received: 03 September 2024

Accepted: 08 October 2024

***Correspondence:**

Dr. Arif A. Faruqui,

E-mail: drfaruqui@gmail.com

Copyright: © the author(s), publisher and licensee Medip Academy. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

ABSTRACT

Urinary tract infections (UTIs) are widespread, with 7 million outpatient visits, 1 million emergency department visits, and 100,000 hospitalizations annually. They mainly affect women aged 20-50. Although antibiotics are the main treatment, around 30% of treated women experience recurrence (rUTI). Regular antibiotic use also raises the risk of antibiotic resistance and side effects. Additionally, antibiotics can disrupt the intestinal and vaginal flora, increasing the risk of recurrence. Therefore, non-antibiotic treatments should be considered to reduce antibiotic use and side effects. Non-antibiotic options such as cranberry juice, D-mannose, probiotics, and potassium magnesium citrate can alleviate UTI symptoms and reduce recurrence risk. Research suggests that combining these non-antibiotic treatments, which work through different mechanisms, leads to better clinical outcomes. This review examines the role of each non-antibiotic treatment, the rationale for their combination, and supports their effectiveness with clinical evidence. Thus, the combination of non-antibiotic treatments may offer a better outcome in patients with UTI and rUTI.

Keywords: Antibiotic, Recurrence, Non-antibiotic, Cranberry, D-mannose, Probiotics

INTRODUCTION

Urinary tract infection (UTI) ranks as one of the most common infectious diseases worldwide.¹ UTI symptoms are a frequent cause for primary care consultations, where the majority of suspected cases are addressed. Uncomplicated lower UTIs typically resolve rapidly and many are self-limiting. Nevertheless, 11% of females have stated experiencing at least one UTI, while 3% have reported having three or more UTIs within the previous year.² UTIs are a major public health issue due to their high occurrence in both community and hospital settings. Symptomatic UTIs result in 7 million outpatient visits, 1 million emergency department visits, and 100,000 hospitalizations annually. With the rise of antimicrobial resistance, these infections not only cause significant morbidity and financial burden but also pose a risk of mortality, particularly among hospitalized patients. A study in India found that UTIs were prevalent in 73.57% of females in outpatient departments, compared to 35.14% in males.³ UTIs are much more prevalent in females,

especially those between the ages of 20 and 50, with a rate of incidence 50 times greater than in men.² Women have a higher susceptibility to UTIs compared to men because of their shorter urethra, lack of prostatic secretions, pregnancy, and the increased risk of urinary tract contamination by fecal bacteria.¹

UTI CLASSIFICATION

UTIs are of two main types: uncomplicated and complicated. Uncomplicated UTIs usually occur in people who are overall healthy and don't have any structural or neurological issues in their urinary tract. Uncomplicated UTIs are further divided into lower UTIs, known as cystitis, and upper UTIs, referred to as pyelonephritis.⁴ The risk of developing cystitis is higher for women due to factors such as a history of UTIs, sexual activity, vaginal infections, diabetes, obesity, and genetic predisposition.^{4,5} Complicated UTIs are associated with conditions that weaken the urinary tract or the body's immune system. The potential concerns could involve urinary blockage, build-

up from neurological disorders, compromised immune function, kidney failure, kidney transplant, pregnancy, and the presence of stones, catheters, or other drainage devices.⁴

CLINICAL PRESENTATION OF UTI

Symptoms of uncomplicated UTIs include: pain while urinating (dysuria), the need to urinate often (frequency), difficulty initiating urination (hesitancy), an immediate urgency to urinate (urgency), pain or discomfort in the area above the pubic bone (suprapubic pain), spasms in the bladder, and blood in the urine (hematuria).⁶

ETIOLOGY OF UTIS

The usual microorganisms that lead to urinary tract infections consist of both positive and negative gram bacteria; along with specific fungi.⁴ The majority of uncomplicated UTI cases are acquired within the community and are mainly caused by uropathogenic *E. coli* (UPEC) and *Klebsiella spp.*, accounting for approximately 75-95% of all cases. Other organisms such as *Proteus spp.*, *Enterobacter spp.*, *Pseudomonas spp.*, *Enterococcus faecalis*, *Staphylococcus saprophyticus*, *Staphylococcus aureus*, and *Candida spp.* may also cause UTI, but their prevalence is lower (Figure 1).^{1,4}




Figure 1: Aetiology of urinary tract infections.⁴

GENERAL MANAGEMENT OF URINARY TRACT INFECTIONS

The cornerstone treatment for bacterial infections of any origin, including a UTI, is antimicrobial therapy. Given the high frequency of UTIs, especially in women, it is essential to initiate the controlled use of antibiotics for treatment.⁷

The most commonly used antimicrobial agents for uncomplicated UTIs are trimethoprim, trimethoprim-sulfamethoxazole, fluoroquinolones, β -lactams, fosfomycin tromethamine and nitrofurantoin. These medications are preferred due to their tolerability, effectiveness against uropathogens, and favorable pharmacokinetics. The resolution of bacteriuria in UTIs is associated with high concentrations of the antimicrobial agent in the urine rather than in the serum.

All approved agents achieve urinary concentrations significantly higher than serum levels. Trimethoprim-sulfamethoxazole and fluoroquinolones are particularly effective for long-term treatment as they target aerobic gram-negative flora while sparing vaginal and fecal anaerobic flora.⁷

RECURRENCE OF URINARY TRACT INFECTIONS

Recurrent urinary tract infections (rUTIs) is defined as person having 2 acute bacterial cystitis occurrence with related symptoms in the last 6 months, or 3 occurrences in the past 12 months. These infections are commonly seen in women.⁸ The majority of women who have UTIs experience positive results with antibiotic therapy, typically seeing symptom improvement within 2 to 4 days. Nevertheless, around 30% of females may encounter a recurrence within a span of 6 months.⁶

PATHOPHYSIOLOGY OF rUTIs

rUTIs often occur due to new bacterial infections. If the infections persist even after treatment, it could be a sign of a urinary stone, or prostatitis or untreated source such as an abscess. Normally, bacteria from the rectum contaminate the peri-urethral area and then move up to the bladder. Studies have revealed an intricate connection between the intestinal, vaginal, and urinary microbiomes. Moreover, *E. coli* is most common bacteria responsible for 75% of rUTIs.⁸

Distinguishing between rapid reinfection (new organism) and relapse (same organism not fully treated) is crucial. Relapse means the infection comes back within two weeks with the same germ, while reinfection happens when a new infection occurs more than two weeks after treatment. Most recurring UTIs are new infections and usually don't need a urological check-up or imaging unless certain signs and symptoms are observed.⁸

rUTIs can be attributed to various risk factors such as, menopause, frequent sexual activity, atrophic vaginitis (untreated), and the use of diaphragms loaded with spermicide. These factors can disrupt the vaginal flora and introduce bacteria into the urethra. Genetic factors can increase the likelihood of recurring UTIs, particularly in cases with a family history of frequent UTIs.⁸

ANTIBIOTICS DRAWBACKS AND NEED FOR NEW ALTERNATIVES IN UTI MANAGEMENT

Antimicrobial agents are typically the initial treatment for UTIs. However, there is increasing concern about antibiotic resistance, making the decision to prescribe antibiotics more complex.⁹ Antibiotics can lead to side effects such as rashes, dizziness, diarrhea, nausea, vomiting, headaches, and yeast infections. In rare cases, they can cause severe allergic reactions.¹⁰ Prolonged use of nitrofurantoin can result in hypersensitivity pneumonitis.¹¹ Additionally, long-term antibiotic use can alter the microbiome, affecting both the gut and urinary tract flora and promoting resistance in uropathogens.^{12,13} The rise of resistant strains like extended-spectrum beta-lactamases and carbapenem-resistant *E. coli* highlights the need for new agents with fewer side effects and better long-term efficacy.¹³ This prompted the exploration of alternative treatments and preventive measures for UTIs.¹⁴ Other alternatives to antibiotics are behavioural modifications, NSAIDs, phytotherapy (like Chinese herbal remedies and cranberry items), D-mannose, probiotics, estrogens, methenamine hippurate, immunostimulants, intravesical glycosaminoglycans, vaccines and inoculation (less harmful bacterial organism).¹⁴ Using these agents combined could offer the best treatment for decreasing rUTIs, and it is essential to carry out trials in particular population segments to confirm their effectiveness.¹⁴

PHYTOTHERAPY IN UTI MANAGEMENT

The history of using plants or their components for medical purposes dates back centuries. Chinese herbal medicine (CHM) and cranberry products have been extensively studied for their potential in preventing and treating UTIs.¹⁴

Cranberries and cranberry-based products

Cranberry, a plant belonging to the *Ericaceae* family, is known by the scientific names *Vaccinium macrocarpon*, *Vaccinium oxycoccos*, and *Vaccinium erythrocarpum*.¹⁴ Cranberries have a high water content of more than 80%

and are comprised of 10% carbohydrates. Additionally, they contain various beneficial compounds like flavonoids, anthocyanins, catechin, triterpenoids, organic acids, and a small quantity of ascorbic acid. The main organic acids found in cranberries consist of citric, malic, and quinic acids, with lesser quantities of benzoic and glucuronic acids.¹⁵ Anthocyanidins and proanthocyanidins, which are tannins (polyphenols), act as a natural defense mechanism in plants to combat microbial infections. These compounds have showed significant benefits in treating UTI infections in women.^{14,15}

Proposed mechanism of cranberry in UTI

In vitro research highlights the significant role of proanthocyanidins, a key compound in cranberries, in preventing UTIs.¹⁴ *E. coli* attaches to urothelial cells to cause UTIs with the help of adhesins like type 1 fimbriae and P fimbriae. These adhesins bind to carbohydrate receptors on the cells to facilitate the attachment process.¹⁶ Most uropathogenic *E. coli* strains produce type 1 fimbriae that target mannose-like receptors, while highly pathogenic strains in recurring UTIs or pyelonephritis also express P fimbriae.¹⁸

Cranberries contain fructose, which inhibits the attachment of type 1 fimbriated *E. coli*, and proanthocyanidins, which prevent P fimbriated *E. coli* from adhering to urothelial cells (Figure 2).¹⁴ Proanthocyanidins, composed of flavan oligomers and polymers, possess anti-adhesive properties that hinder various bacteria, including *Pseudomonas aeruginosa*, *E. coli*, and *Proteus mirabilis*.^{19,20} Cranberries are unique due to their A-type linkage in proanthocyanidins, crucial for preventing *E. coli* adhesion.²¹

Although the exact mechanism is not fully understood, cranberry components may act as receptor analogs, inhibits *E. coli* adhesion by binding to fimbrial tips competitively.¹⁸ They can also alter bacterial cell surface properties, reducing fimbrial length and density, thus lowering adherence to urothelial cells.¹⁸ Extended cranberry exposure can morphologically transform *E. coli*, making them more likely to be repelled by urothelial cells (Figure 2).²²

Additionally, ursolic acid in cranberries can synergize with proanthocyanidins to alter *E. coli* gene expression, preventing biofilm formation. Laboratory studies showed that 10 µg of ursolic acid significantly reduced *E. coli* biofilm formation, with DNA microarray analysis indicating that ursolic acid activates genes related to chemotaxis, mobility, and heat shock response, thereby hindering mature biofilm development.²³

D-MANNOSE IN URINARY TRACT INFECTIONS

D-mannose is crucial for the glycosylation of proteins, including monoclonal antibodies. It is quickly absorbed when taken orally and appears in the bloodstream within

30 minutes, eventually being excreted through the urinary system.²⁴ Research has demonstrated that D-mannose has the potential to be an effective preventive treatment for rUTIs.²⁵

Proposed mechanism of action for D-mannose

Type 1 fimbriae, or pili, are protein projections in enteric bacteria like *E. coli* that are essential for attachment.²⁶ They are composed of Fim proteins, with the FimH adhesion molecule at the tip, which binds to mannosylated host proteins on the urinary tract, such as uroplakin 1a, Tamm-Horsfall glycoprotein, and beta-1 and alpha-3 integrins. FimH is crucial for the development of UTIs caused by *E. coli*, making it a potential target for UTI treatments.²⁷ D-mannose, which resembles the binding sites of urothelial glycoprotein receptors, can saturate FimH adhesins in the urine, preventing bacterial attachment. An in vitro study showed that D-mannose completely prevented adherence in 42% of *E. coli* strains and reduced adherence by at least 50% in 18% of strains from clinical isolates.²⁹ Thus, D-mannose combats UTIs caused by *E. coli* mainly by resembling urothelial glycoprotein receptors such as uroplakin. This resemblance enables D-mannose to saturate FimH adhesins on type 1 pili, which are essential for bacterial attachment to the urinary tract lining. Consequently, D-mannose hinders *E. coli* from binding to host receptors, leading to decreased adherence and potentially lessening the severity of UTIs.

PROBIOTICS

Probiotics, living organisms ingested for health benefits, play a crucial role in maintaining the normal bacterial flora in humans. This flora acts as a vital defense mechanism against infections. Consequently, replenishing the vaginal and intestinal flora with probiotics is an attractive

approach for preventing infections. In healthy women, the balanced vaginal ecosystem is safeguarded by normal flora, which aids in repelling pathogenic bacteria that may cause UTIs. Among these, *Lactobacilli* species are especially significant in preserving the healthy vaginal flora and in hindering the attachment and movement of pathogens to the bladder and urothelium.³⁰ Lower levels of *Lactobacilli* in the vagina have been associated with increased colonization of *E. coli*. Various factors, including sexual activity, the use of spermicides in post-menopausal women, and frequent antibiotic use, contribute to the decrease in vaginal *Lactobacilli* levels.¹⁴

Proposed mechanism of action for probiotics

Lactobacilli spp. produces multifaceted approach to preventing UTI. *Lactobacilli*, a beneficial bacterial species, employs following mechanisms to help prevent UTIs.

Competitive inhibition of uropathogen adhesion

Lactobacilli compete with uropathogens (bacteria that can cause UTIs) for adhesion receptors present on epithelial cells in vagina. *Lactobacillus* in the vagina prevents uropathogens from successfully colonizing through exclusion, competition, and displacement mechanisms. *Lactobacilli* take up binding sites, compete for adhesion receptors, and can displace uropathogens already attached to vaginal cells, thus preventing their establishment.³¹

Production of antimicrobial compounds

Lactobacilli generate a range of antimicrobial compounds, such as hydrogen peroxide, lactic acid, and bacteriocins which are antimicrobial proteins. These compounds create an acidic environment that is inhospitable for uropathogens.³²




Figure 2: Cranberry components and their mechanism of action for UTI prevention. Fructose inhibits the binding of type 1 fimbriae to uroplakin receptors, while proanthocyanidins prevent the binding of P fimbriae to glycolipid receptors.¹⁴

Inhibition of biofilm formation

When lactobacilli coaggregate or cluster with uropathogens, it concentrates the antimicrobial compounds near the uropathogens. This hinders the uropathogens' capacity to create defensive biofilms - clusters of bacteria surrounded by a self-generated extracellular matrix. Biofilms make infections more difficult to treat.^{33,34}

Downregulation of inflammation

The concentrated antimicrobials also suppress the production of certain proinflammatory cytokines, such as IL-6, IL-8, IL-10 and tumor necrosis factor. This helps reduce the inflammatory response that can accompany UTIs.^{34,35}

By employing this multifaceted approach inhibiting uropathogen adhesion, producing antimicrobials, disrupting biofilms, and dampening inflammation lactobacilli play a key role in preventing and managing urinary tract infections. In addition to their mechanisms for preventing urinary tract infections, research has demonstrated that lactobacilli can also exhibit antimicrobial effects against certain problematic bacterial strains. *Lactobacilli* exhibit antimicrobial activity against resistant pathogens. *Lactobacilli*, particularly *L. plantarum* and *L. fermentum*, have demonstrated inhibitory activity against extended-spectrum beta-lactamase (ESBL)-producing *E. coli* and multidrug-resistant organisms. These two specific species of lactobacilli have exhibited the most pronounced antimicrobial effects, suggesting their potential as natural alternatives or adjuncts to conventional antibiotics in combating the growing threat of antibiotic resistance. The inhibitory properties of these lactobacilli may be attributed to their ability to produce antimicrobial compounds, compete for nutrients and adhesion sites, and modulate the host immune response, making them promising candidates for further research and development in the field of antimicrobial therapy.^{36,37}

Limited research has been conducted on the use of oral probiotics in adults with recurrent UTI compared to studies in children. In a randomized trial with postmenopausal females (n=252) with recurrent UTIs, received either oral probiotics or antibiotic prophylaxis. The study found that probiotics reduced UTI recurrence from 6.8% to 3.3% over one year but did not meet the non-inferiority criteria compared to antibiotics. Notably, the probiotic group did not develop antibiotic resistance, while the antibiotic group had a 95% resistance rate after just 30 days.³⁸ These results indicate that oral probiotics may be a more favorable choice than antibiotics for a large number of patients with UTI.

POTASSIUM MAGNESIUM CITRATE

Dysuria, a common symptom of UTI, is referred as painful or uncomfortable sensation while urinating.³⁹ Dysuria in

women may indicate the simultaneous presence of urinary tract inflammation and infection. Pain experienced at the onset or during urination is indicative of the existence of infection and inflammation.⁴⁰ Urinary alkalinizing agents are commonly utilized in certain regions for the symptomatic control of uncomplicated UTIs, and they are endorsed in specific national drug formularies.⁴¹ Potassium citrate is recommended for alleviating the symptoms of dysuria linked to minor urinary tract infections, particularly cystitis.⁴² This medication functions by alkalinizing the urine, thereby decreasing irritation during urination.⁴²

RATIONALE FOR COMBINATION

UTIs are widespread, causing significant patient suffering, resulting in substantial financial burdens on healthcare systems, and are a leading cause of antibiotic consumption globally. The increasing challenge of antimicrobial resistance underscores the urgent need to explore non-antibiotic options for managing and preventing UTIs. Possible alternatives to antibiotics for UTI treatment and prevention encompass cranberry juice, D-mannose, probiotics, and alkalinizing agents.^{14,43}

It may be necessary to conduct trials in specific population groups in order to determine the most effective treatment for reducing recurrent UTI, which could involve a combination of these agents.¹⁴

Cranberry proanthocyanidins have the ability to prevent the attachment of P-fimbriated *E. coli* to bladder and vaginal epithelial cells in a manner that is dependent on the dosage. P-fimbriae are responsible for enabling bacteria to adhere to the urinary tract, especially the kidneys.^{43,44} Cranberry proanthocyanidins blocks the P-type fimbriae on bacteria, which prevents the bacteria from sticking to the cells of the urinary tract.^{43,44} Although the search results do not explicitly state the binding of D-mannose to type-1 fimbriae, certain research studies have indicated that D-mannose could potentially exhibit anti-adhesive properties against uropathogenic *E. coli* through its interference with type-1 fimbriae.¹⁴ This accelerates removal of uropathogens through urine.

Proanthocyanidins (type A) found in cranberries are known for their powerful ability to inhibit mannose-resistant adhesins. Cranberries can also lead to the detachment of bacteria that are adhering to uroepithelial cells. D-mannose works by saturating FimH adhesins on type 1 pili, which in turn prevents *E. coli* from binding to host receptors, reducing adherence and potentially lessening the severity of UTIs.⁴⁴

Probiotics produces multifaceted approach to preventing UTI. Lactobacilli, a beneficial bacterial species, prevent urinary tract infections through competitive inhibition of uropathogen adhesion, production of antimicrobial compounds, inhibition of biofilm formation, and downregulation of inflammation.¹⁴ Potassium magnesium citrate can help make the urine less acidic, thereby

reducing irritation during urination. Thus, combination of cranberries, D-mannose, probiotics, and potassium citrate will be well tolerated and result in significant control of urinary infections and its recurrence.⁴³

CLINICAL EVIDENCES OF COMBINATION

Lower UTIs are prevalent among women and can be easily treated, but the use of antibiotics for treatment and prevention of recurrence has disadvantages such as contributing to antimicrobial resistance and intestinal imbalance. As a result, researchers are investigating alternative therapies.⁴⁵ Combining cranberry extract with D-mannose may be an effective method for managing acute UTIs. In a pilot study with 93 healthy, non-pregnant women, participants received either a recommended antibiotic alone or with cranberry extract plus D-mannose, followed by a clinical examination on day 7. Those who improved or were cured entered a double-blind phase, and received the combination product or a placebo for more 21 days before a next examination. The combination product resulted in higher cure rates at day 7 (91.6% versus 84.4%) and significantly improved cure rates for antibiotic-resistant strains (88.8% versus 37.5%, $p < 0.0001$). This suggests that cranberry extract in combination with D-mannose is promising for managing acute UTIs, especially in resistant cases.⁴⁵

In addition, utilizing a combination of non-antibiotic methods may lead to improved results compared to the use of a single treatment approach. A recent small-scale trial involving 33 premenopausal women demonstrated that the administration of d-mannose, cranberry extract, and lactobacilli in powder form effectively managed symptoms of acute uncomplicated cystitis and UTI. Throughout the study, participants received two doses of the combination daily for the initial month, followed by one sachet per day until the 60th day. By the conclusion of the trial, all subjects tested negative for nitrites and leukocyte esterase in their urine dipstick examination.⁴⁶

Another study was conducted to assess the efficacy of a novel blend of D-mannose, pomegranate plant extract, prebiotics, and probiotics in relieving symptoms in women with acute uncomplicated cystitis. The research took place at Villa Stuart Private Hospital from September to November 2018. Participants took the combination of cranberry extract and D-mannose twice daily for 5 days, then once daily for 10 days, along with increased fluid intake. Antibiotics were reserved for cases of symptom exacerbation. Thirty-three women with an average age of 38.1 ± 11.2 years completed the study. Results indicated a notable improvement in symptoms: 30.3% of women were symptom-free by day 15, rising to 90.9% by day 30. Symptoms persisted in 48.5% of women at day 15 and 9.1% at day 30, with no deterioration by the end of the study period. Both the acute cystitis symptom score (ACSS) and quality of life (QoL) assessments displayed significant enhancements. Six patients required antibiotics, and there were no reported adverse events. The

findings suggest that this combination effectively alleviates acute cystitis symptoms in the majority of cases without the need for antibiotics, although the absence of microbiological evaluation, a control group, and potential confounding factors related to increased fluid intake are acknowledged as study limitations.⁴⁷

CONCLUSION

The key approach to managing rUTIs is to disrupt the cycle of infection and address any reversible factors. While antibiotics are a common treatment, they can lead to the development of bacterial resistance. Approximately one in four women experience recurring UTIs and are more susceptible to such infections. Non-antibiotic therapies, such as cranberry products, D-mannose, and probiotics, offer alternative options for treating and preventing UTIs. These therapies can help prevent bacterial adhesion to uroepithelial cells, slow down bacterial metabolism, and create an unfavorable environment for pathogens. By combining cranberry, D-mannose, and probiotics, individuals can reduce the risk of UTI recurrence and maintain a healthy urinary tract. This comprehensive approach, as suggested by recent reviews, is a promising alternative to antibiotic treatment for managing UTIs.

ACKNOWLEDGEMENTS

Author would like to acknowledge the contribution of Ms. Richa Deliwala, M. Pharm (Pharmacology) and Mr. Rafique Sheikh M. Pharm (Pharmacology) for their contribution in doing literature search and helping with the preparation of manuscript.

Funding: No funding sources

Conflict of interest: None declared

Ethical approval: Not required

REFERENCES

1. Mohapatra S, Panigrahy R, Tak V, Shwetha JV, Sneha KC, Chaudhuri S, et al. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. *Access Microbiol.* 2022;4(2):000321.
2. Pujades-Rodriguez M, West RM, Wilcox MH, Sandoe J. Lower Urinary Tract Infections: Management, Outcomes and Risk Factors for Antibiotic Re-prescription in Primary Care. *E Clin Med.* 2019;14:23-31.
3. Resistance Pattern in UTI: Indian and International Perspectives. Walter Bushnell Healthcare Foundation. Available at: <https://wbhf.walterbushnell.com/publications/bush-beats/item/67-resistance-pattern-in-uti-indian-and-international-perspectives#>. Accessed on 17 August 2024.
4. Flores-Mireles AL, Walker JN, Caparon M, Hultgren SJ. Urinary tract infections: epidemiology, mechanisms of infection and treatment options. *Nat Rev Microbiol.* 2015;13(5):269-84.

5. Hannan TJ, Totsika M, Mansfield KJ, Moore KH, Schembri MA, Hultgren SJ. Host-pathogen checkpoints and population bottlenecks in persistent and intracellular uropathogenic *Escherichia coli* bladder infection. *FEMS Microbiol Rev.* 2012;36(3):616-48.
6. Abou Heidar NF, Degheili JA, Yacoubian AA, Khauli RB. Management of urinary tract infection in women: A practical approach for everyday practice. *Urol Ann.* 2019;11(4):339-46.
7. Jancel T, Dudas V. Management of uncomplicated urinary tract infections. *West J Med.* 2002;176(1):51-5.
8. Aggarwal N, Leslie SW, Lotfollahzadeh S. Recurrent Urinary Tract Infections. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
9. Amawi HA, U'wais HT, Nusair MB, Al-okour R, Amawi S, Al-Shatnawi S, et al. Management of urinary tract infections and antibiotic susceptibility patterns of bacterial isolates. *Int J Clin Pract.* 2021;75(10):e14475.
10. Begum J. Antibiotics for UTI Treatment. WebMD. Available at: <https://www.webmd.com/a-to-z-guides/what-are-antibiotics-for-uti>. Accessed on 12 May 2024.
11. Sabih A, Leslie SW. Complicated Urinary Tract Infections. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing. 2024.
12. Kenneally C, Murphy CP, Sleator RD, Culligan EP. The urinary microbiome and biological therapeutics: Novel therapies for urinary tract infections. *Microbiol Res.* 2022;259:127010.
13. Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: How promising is the use of probiotics? *Indian J Med Microbiol.* 2017;35(3):347-54.
14. Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. *Nat Rev Urol.* 2018;15(12):750-76.
15. Raz R, Chazan B, Dan M. Cranberry Juice and Urinary Tract Infection. *Clin Infect Dis.* 2004;143(12):891-4.
16. Lynch DM. Cranberry for prevention of urinary tract infections. *Am Fam Physician.* 2004;70(11):2175-7.
17. Ofek I, Beachey EH. Mannose binding and epithelial cell adherence of *Escherichia coli*. *Infect Immun.* 1978;22(1):247-54.
18. Hisano M, Bruschini H, Nicodemo AC, Srougi M. Cranberries and lower urinary tract infection prevention. *Clinics (Sao Paulo).* 2012;67(6):661-8.
19. Hidalgo G, Chan M, Tufenkji N. Inhibition of *Escherichia coli* CFT073 *fliC* expression and motility by cranberry materials. *Appl Environ Microbiol.* 2011;77(19):6852-7.
20. O'May C, Tufenkji N. The swarming motility of *Pseudomonas aeruginosa* is blocked by cranberry proanthocyanidins and other tannin-containing materials. *Appl Environ Microbiol.* 2011;77(9):3061-7.
21. Howell AB, Reed JD, Krueger CG, Winterbottom R, Cunningham DG, Leahy M. A-type cranberry proanthocyanidins and uropathogenic bacterial anti-adhesion activity. *Phytochemistry.* 2005;66(18):2281-91.
22. Liu Y, Black MA, Caron L, Camesano TA. Role of cranberry juice on molecular-scale surface characteristics and adhesion behavior of *Escherichia coli*. *Biotechnol Bioeng.* 2006;93(2):297-305.
23. Ren D, Zuo R, González Barrios AF, Bedzyk LA, Eldridge GR, Pasmore ME, et al. Differential gene expression for investigation of *Escherichia coli* biofilm inhibition by plant extract ursolic acid. *Appl Environ Microbiol.* 2005;71(7):4022-34.
24. Davis JA, Freeze HH. Studies of mannose metabolism and effects of long-term mannose ingestion in the mouse. *Biochim Biophys Acta.* 2001;1528(2-3):116-26.
25. Fettweis JM, Brooks JP, Serrano MG, Sheth NU, Girerd PH, Edwards DJ, et al. Differences in vaginal microbiome in African American women versus women of European ancestry. *Microbiology (Reading).* 2014;160(Pt 10):2272-82.
26. Fronzes R, Remaut H, Waksman G. Architectures and biogenesis of non-flagellar protein appendages in Gram-negative bacteria. *EMBO J.* 2008;27(17):2271-80.
27. Mydock-McGrane LK, Cusumano ZT, Janetka JW. Mannose-derived FimH antagonists: a promising antivirulence therapeutic strategy for urinary tract infections and Crohn's disease. *Expert Opin Ther Pat.* 2016;26(2):175-97.
28. Michaels EK, Chmiel JS, Plotkin BJ, Schaeffer AJ. Effect of D-mannose and D-glucose on *Escherichia coli* bacteriuria in rats. *Urol Res.* 1983;11(2):97-102.
29. Schaeffer AJ, Chmiel JS, Duncan JL, Falkowski WS. Mannose-sensitive adherence of *Escherichia coli* to epithelial cells from women with recurrent urinary tract infections. *J Urol.* 1984;131(5):906-10.
30. Velraeds MM, van der Mei HC, Reid G, Busscher HJ. Inhibition of initial adhesion of uropathogenic *Enterococcus faecalis* by biosurfactants from *Lactobacillus* isolates. *Appl Environ Microbiol.* 1996;62(6):1958-63.
31. Andreu A, Stapleton AE, Fennell CL, Hillier SL, Stamm WE. Hemagglutination, adherence, and surface properties of vaginal *Lactobacillus* species. *J Infect Dis.* 1995;171(5):1237-43.
32. Osset J, Bartolomé RM, García E, Andreu A. Assessment of the capacity of *Lactobacillus* to inhibit the growth of uropathogens and block their adhesion to vaginal epithelial cells. *J Infect Dis.* 2001;183(3):485-91.
33. Mastromarino P, Brigidi P, Macchia S, Maggi L, Pirovano F, Trinchieri V, et al. Characterization and selection of vaginal *Lactobacillus* strains for the preparation of vaginal tablets. *J Appl Microbiol.* 2002;93(5):884-93.

34. Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. *Clin Ther.* 2008;30(3):453-68.
35. Zárate G, Nader-Macias ME. Influence of probiotic vaginal lactobacilli on in vitro adhesion of urogenital pathogens to vaginal epithelial cells. *Lett Appl Microbiol.* 2006;43(2):174-80.
36. Manzoor A, Ul-Haq I, Baig S, Qazi JI, Seratlic S. Efficacy of Locally Isolated Lactic Acid Bacteria Against Antibiotic-Resistant Uropathogens. *Jundishapur J Microbiol.* 2016;9(1):e18952.
37. Shim YH, Lee SJ, Lee JW. Antimicrobial activity of lactobacillus strains against uropathogens. *Pediatr Int.* 2016;58(10):1009-13.
38. Beerepoot MA, ter Riet G, Nys S, van der Wal WM, de Borgie CA, de Reijke TM, et al. Lactobacilli vs antibiotics to prevent urinary tract infections: a randomized, double-blind, noninferiority trial in postmenopausal women. *Arch Intern Med.* 2012;172(9):704-12.
39. Mehta P, Leslie SW, Reddivari AKR. Dysuria. In: *StatPearls.* Treasure Island (FL): StatPearls Publishing. 2024.
40. Wrenn K. Dysuria, Frequency, and Urgency. In: Walker HK, Hall WD, Hurst JW, editors. *Clinical Methods: The History, Physical, and Laboratory Examinations.* 3rd edition. Boston: Butterworths. 1990.
41. O'Kane DB, Dave SK, Gore N, Patel F, Hoffmann TC, Trill JL, et al. Urinary alkalinisation for symptomatic uncomplicated urinary tract infection in women. *Cochrane Database Syst Rev.* 2016;4(4):CD010745.
42. EMC. Potassium citrate (mixture). Medicines UK. Available at: <https://www.medicines.org.uk/emc/landing?status=1#gref>. Accessed on 12 May 2024.
43. Gupta K, Chou MY, Howell A, Wobbe C, Grady R, Stapleton AE. Cranberry products inhibit adherence of p-fimbriated Escherichia coli to primary cultured bladder and vaginal epithelial cells. *J Urol.* 2007;177(6):2357-60.
44. Howell AB, Vorsa N, Der Marderosian A, Foo LY. Inhibition of the adherence of P-fimbriated Escherichia coli to uroepithelial-cell surfaces by proanthocyanidin extracts from cranberries. *N Engl J Med.* 1998;339(15):1085-6.
45. Rădulescu D, David C, Turcu FL, Spătaru DM, Popescu P, Văcăroiu IA. Combination of cranberry extract and D-mannose - possible enhancer of uropathogen sensitivity to antibiotics in acute therapy of urinary tract infections: Results of a pilot study. *Exp Ther Med.* 2020;20(4):3399-406.
46. Vicariotto F. Effectiveness of an association of a cranberry dry extract, D-mannose, and the two microorganisms Lactobacillus plantarum LP01 and Lactobacillus paracasei LPC09 in women affected by cystitis: a pilot study. *J Clin Gastroenterol.* 2014;48(1):S96-101.
47. Pugliese D, Acampora A, Porreca A, Schips L, Cindolo L. Effectiveness of a novel oral combination of D-Mannose, pomegranate extract, prebiotics and probiotics in the treatment of acute cystitis in women. *Arch Ital Urol Androl.* 2020;92(1):34-8.

Cite this article as: Faruqui AA. Prevention and management of urinary tract infection: a non-antibiotic multi-modal approach. *Int J Reprod Contracept Obstet Gynecol* 2024;13:3440-7.